The Smarticles delivery technology has been licensed to ProNAi, for delivery of single-stranded oligonucleotide therapeutics and to Mirna for delivery of double-stranded microRNA mimics.
Marina R&D executive vice president Richard Ho said the company is currently applying DiLA2 and SMARTICLES, in both in-house preclinical efforts as well as through licensing collaborations with Debiopharm and Mirna respectively.
"This patent is part of our larger global portfolio of delivery compound patents, which ensures the broadest patent protection available to us for our nucleic acid delivery development efforts," Ho added.